Compare Stocks: IMTX, ACAD, PBLS, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$28.02 +0.6%	$27.30	$19.69 ▼ $30.96	$4.80B	0.86	1.49 million shs	1.68 million shs
DYN Dyne Therapeutics	$24.28 -2.7%	$24.80	$11.92 ▼ $27.31	$4.66B	1.08	1.71 million shs	1.59 million shs
IMTX Immatics	$9.56 +1.1%	$9.42	$5.67 ▼ $12.41	$1.31B	1.33	599,808 shs	497,159 shs
PBLS Parabilis Medicines	$40.42 -0.8%	$34.15	$24.51 ▼ $41.49	$5.03B	N/A	370,000 shs	380,692 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.57%	-3.74%	-2.71%	+29.96%	+8.94%
DYN Dyne Therapeutics	-2.69%	-3.15%	-7.22%	+42.49%	+80.12%
IMTX Immatics	+1.06%	+1.16%	-2.15%	-2.35%	+75.41%
PBLS Parabilis Medicines	-0.81%	+3.35%	+15.82%	+4,041,999,900.00%	+4,041,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$28.02 +0.6%	$27.30	$19.69 ▼ $30.96	$4.80B	0.86	1.49 million shs	1.68 million shs
DYN Dyne Therapeutics	$24.28 -2.7%	$24.80	$11.92 ▼ $27.31	$4.66B	1.08	1.71 million shs	1.59 million shs
IMTX Immatics	$9.56 +1.1%	$9.42	$5.67 ▼ $12.41	$1.31B	1.33	599,808 shs	497,159 shs
PBLS Parabilis Medicines	$40.42 -0.8%	$34.15	$24.51 ▼ $41.49	$5.03B	N/A	370,000 shs	380,692 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.57%	-3.74%	-2.71%	+29.96%	+8.94%
DYN Dyne Therapeutics	-2.69%	-3.15%	-7.22%	+42.49%	+80.12%
IMTX Immatics	+1.06%	+1.16%	-2.15%	-2.35%	+75.41%
PBLS Parabilis Medicines	-0.81%	+3.35%	+15.82%	+4,041,999,900.00%	+4,041,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	22.63% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	41.75% Upside
IMTX Immatics	2.63	Moderate Buy	$20.60	115.48% Upside
PBLS Parabilis Medicines	3.00	Buy	$41.67	3.08% Upside

Current Analyst Ratings Breakdown

Latest IMTX, ACAD, PBLS, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.14B	4.24	$0.89 per share	31.40	$7.58 per share	3.70
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A
IMTX Immatics	$41.70M	31.33	N/A	N/A	$3.47 per share	2.76
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	12.62	28.59	20.77	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IMTX, ACAD, PBLS, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
DYN Dyne Therapeutics	0.28	12.02	12.02
IMTX Immatics	N/A	7.54	7.54
PBLS Parabilis Medicines	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
DYN Dyne Therapeutics	96.68%
IMTX Immatics	64.41%
PBLS Parabilis Medicines	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
DYN Dyne Therapeutics	9.46%
IMTX Immatics	3.30%
PBLS Parabilis Medicines	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
IMTX Immatics	260	136.69 million	129.65 million	Optionable
PBLS Parabilis Medicines	N/A	123.53 million	N/A	N/A

IMTX, ACAD, PBLS, and DYN Headlines

Recent News About These Companies

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026 | globenewswire.com

ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS

August 31, 2026 | marketbeat.com

Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS

August 29, 2026 | marketbeat.com

1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC

August 28, 2026 | marketbeat.com

venBio Partners LLC Purchases Shares of 5,266,697 Parabilis Medicines, Inc. $PBLS

August 28, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS

August 28, 2026 | marketbeat.com

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts

August 26, 2026 | marketbeat.com

ARCH Venture Management LLC Makes New $175.52 Billion Investment in Parabilis Medicines, Inc. $PBLS

August 26, 2026 | marketbeat.com

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

August 25, 2026 | markets.businessinsider.com

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

August 25, 2026 | globenewswire.com

ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS

August 24, 2026 | marketbeat.com

Éléments financiers clés - PBLS

August 23, 2026 | fr.investing.com

Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9% - Here's What Happened

August 18, 2026 | marketbeat.com

Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS

August 18, 2026 | marketbeat.com

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year High - What's Next?

August 17, 2026 | marketbeat.com

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

August 14, 2026 | seekingalpha.com

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell

August 13, 2026 | finance.yahoo.com

Parabilis Medicines: Q2 Earnings Snapshot

August 13, 2026 | finance.yahoo.com

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | globenewswire.com

Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year High - What's Next?

August 10, 2026 | marketbeat.com

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

July 6, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, ACAD, PBLS, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$28.02 +0.16 (+0.57%)

As of 09/4/2026 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Dyne Therapeutics NASDAQ:DYN

$24.28 -0.67 (-2.69%)

As of 09/4/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Immatics NASDAQ:IMTX

$9.56 +0.10 (+1.06%)

As of 09/4/2026 04:00 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Parabilis Medicines NASDAQ:PBLS

$40.42 -0.33 (-0.81%)

As of 09/4/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMTX, ACAD, PBLS, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMTX, ACAD, PBLS, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMTX, ACAD, PBLS, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, ACAD, PBLS, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Dyne Therapeutics NASDAQ:DYN

Immatics NASDAQ:IMTX

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMTX, ACAD, PBLS, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMTX, ACAD, PBLS, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMTX, ACAD, PBLS, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, ACAD, PBLS, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Dyne Therapeutics NASDAQ:DYN

Immatics NASDAQ:IMTX

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools